Feeding Disorders, Infant of Diabetic Mother, Oxidative Stress, Vagus Nerve Stimulation
Conditions
Brief summary
Infants of diabetic mothers who are failing to learn oral feeding by term age equivalence have greater CNS oxidative stress, which interact to predict poor neuroplasticity response to transcutaneous vagus nerve stimulation paired with oral feeding. We propose treating the oxidative stress in IDM infants prior to initiating taVNS, with an FDA-approved antioxidant (N-acetylcysteine, NAC) to improve CNS oxidative stress, which in turn regulates expression of many genes including BDNF, that may enhance motor learning.
Detailed description
Our group has recently conducted a first-in-infants pilot trial of pairing transcutaneous auricular vagus nerve stimulation (taVNS) with feeding to assist learning oromotor skills. We are enrolling preterm and HIE infants who are failing to learn oral feeds and clinically determined to need a G-tube. In preliminary data, taVNS paired with one or two daily feedings for 2 weeks resulted in 50% of infants attaining full feeds and avoiding G-tube. A notable number of non-responders were infants of diabetic mothers (IDM) exposed to poor glucose control during pregnancy, all of whom required a G-tube. Uncontrolled maternal hyperglycemia is associated with increased systemic and neuro-inflammation, CNS oxidative stress, DNA damage, and worse neonatal outcomes compared to infants of euglycemic mothers. In neonatal animal models, hyperglycemia has been shown to decrease BDNF, alter long-term synaptogenesis and hippocampal neurochemistry, with ongoing CNS oxidative stress and inhibition of the cortical neuronal plasticity required for learning. In our pilot trial of taVNS-paired feeding, CNS glutathione concentrations (GSH), a MR spectroscopy (MRS) marker of oxidative stress, had significant interaction with IDM in predicting outcome, strongly suggesting that ongoing CNS oxidative stress contributes to neuropathology in IDMs failing oral feeding. NAC is an FDA-approved antioxidant that is safe and crosses the blood brain barrier, increasing CNS GSH. NAC reduces CNS oxidative stress, enhances learning and provides a neuroprotective effect after brain injury in our and others neonatal HI and neuroinflammatory animal models. Both GSH and BDNF enhance neuroplasticity. Therefore, we hypothesize that pre-treatment with NAC in IDMs who are failing oral feeding, followed by taVNS-paired feeding, will decrease oxidative stress induced by maternal hyperglycemia and IDM-associated brain injury, and increase response to taVNS-paired feeding rehabilitation.
Interventions
NAC x 14 days, taVNS x 10 days
Sponsors
Study design
Masking description
Co-investigator analyzing MRI data will be blinded to timing of MRI scan and dose
Intervention model description
We will obtain parental consent, and then administer NAC 100mg/kg loading dose, followed by 75mg/kg q 6h via nasogastric tube, started 4 days prior to taVNS-paired feeding and continued for a total of 14 days. We will perform pharmacokinetics of oral NAC, and MRIs prior to, after 3-4 days of NAC, and after taVNS treatment period.
Eligibility
Inclusion criteria
* Infants of diabetic mothers who are failing oral feeding, \>39weeks gestation at enrollment, who are clinically stable, on minimal respiratory support (nasal cannula or room air), and clinical team has determined are G-tube candidates
Exclusion criteria
* Unstable infants or those requiring positive pressure respiratory support * Infants \<39 weeks gestation at enrollment * Major unrepaired congenital anomalies or anomalies that limit feeding volumes * Infants with cardiomyopathy * Repeated episodes of autonomic instability (apnea/ bradycardia) not self resolving
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Daily Oral Feeding Volumes : Difference in Mean Increase | Day -14 to 0, Day 1 to 18 | Difference in the Mean daily change in oral feeding volume(reported in in ml/kg/d) from Day 1-18 days of NAC+taVNS treatment minus Days -14 to 0 (baseline) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Metabolite Concentrations in Basal Ganglia | baseline to 4 days | Change in \[GSH\] by MRS from baseline to day 4 of NAC |
Countries
United States
Participant flow
Recruitment details
Recruitment from 8.12.21 to 3.1.23 in the Neonatal intensive care unit of the Medical University of South Carolina
Participants by arm
| Arm | Count |
|---|---|
| NAC + taVNS NAC will be given via nasogastric tube (n,g.) 75mg/kg/dose or 100mg/kg n.g. q 6h, administered 1h before a feed, for a total of 14 days. taVNS will be administered to left ear during active sucking with 2 daily feedings starting after 4 days of NAC, continuing for 14 days.
N acetyl cysteine + vagus nerve stimulation: NAC x 14 days, taVNS x 14days | 10 |
| Total | 10 |
Baseline characteristics
| Characteristic | NAC + taVNS |
|---|---|
| Age, Continuous | 41.1 weeks post menstrual age STANDARD_DEVIATION 1.1 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 9 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| mean daily oral feeding volume of formula or breast milk | 47 ml/kg/day STANDARD_DEVIATION 29 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants |
| Race (NIH/OMB) More than one race | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 5 Participants |
| Region of Enrollment United States | 10 participants |
| Sex: Female, Male Female | 4 Participants |
| Sex: Female, Male Male | 6 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 1 / 10 |
| other Total, other adverse events | 2 / 10 |
| serious Total, serious adverse events | 0 / 10 |
Outcome results
Daily Oral Feeding Volumes : Difference in Mean Increase
Difference in the Mean daily change in oral feeding volume(reported in in ml/kg/d) from Day 1-18 days of NAC+taVNS treatment minus Days -14 to 0 (baseline)
Time frame: Day -14 to 0, Day 1 to 18
Population: infants of diabetic mothers failing oral feeds in G-tube discussions
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| NAC + taVNS | Daily Oral Feeding Volumes : Difference in Mean Increase | 2.1 ml/kg/day po daily change | Standard Deviation 0.4 |
Metabolite Concentrations in Basal Ganglia
Change in \[GSH\] by MRS from baseline to day 4 of NAC
Time frame: baseline to 4 days
Population: participants with adequate MRS spectra for analysis
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| NAC + taVNS | Metabolite Concentrations in Basal Ganglia | 0.13 mM | Standard Deviation 0.08 |